Every Atlantic Canadian Child, Equally Protected Against Pneumococcal Disease
News originally published by
EIN Presswire
NOVA SCOTIA, CANADA, November 20, 2026 /EINPresswire.com/ -- Babies in British Columbia and Québec now receive a vaccine covering five more serotypes; consortium urges Nova Scotia, New Brunswick, Prince Edward Island and Newfoundland and Labrador to close the gap
On National Child Day, the Pneumonia Awareness Consortium released a position statement today asking the four Atlantic provinces to offer the 20-valent pneumococcal conjugate vaccine (PCV20) to every infant in their routine immunization programs.
Pneumococcal bacteria cause invasive pneumococcal disease, including meningitis, bloodstream infections and pneumonia. Young children are among those at greatest risk. Infants in Atlantic Canada currently receive the 15-valent vaccine (PCV15). British Columbia moved its routine infant program to PCV20 in July 2025, and Québec followed in 2026.
The five serotypes PCV20 adds to PCV15 accounted for roughly one in four invasive pneumococcal disease isolates from Canadian children under five in 2023, including the most common serotype in infants under two, according to national surveillance data.
Canada’s National Advisory Committee on Immunization considers both PCV15 and PCV20 appropriate for healthy children, and expects PCV20, with its five additional serotypes, to have a larger impact on invasive pneumococcal disease.
The statement asks provincial governments to:
• offer PCV20 to every infant in the routine program;
• act together as a region, sharing implementation tools, public messaging and clinician training;
• ensure children at higher risk receive PCV20 on the four-dose schedule recommended nationally;
• measure and report results each year, starting with vaccine coverage and serotype-specific disease in young children.
The consortium also commends the public health teams, immunizers and families across the region whose work has built strong infant vaccination programs in all four provinces.
A message for parents: Keep your child’s vaccines on schedule. The vaccine Atlantic infants receive today protects well against the 15 serotypes it covers. Parents with questions should speak with their health-care provider or local public health office.
The full statement, Every Canadian Atlantic Child, Equally Protected, is available in English and French at https://pneumoawareness.ca/every-atlantic-canadian-child-equally-protected/.
Quotes
“Pneumococcal meningitis and bloodstream infections can progress quickly in young children, and some children are left with lasting hearing loss or neurological disability. Where a child is born shouldn’t decide how broadly they’re protected. Atlantic provinces have strong infant immunization programs, and offering PCV20 to every baby is a natural next step that builds on that work.”
— Craig Thompson, Chair, Society for Intelligence Management (SIM) Canada and the Pneumonia Awareness Consortium
“When we talk about protecting children’s lung health, flu and RSV often dominate the conversation. Yet pneumococcal bacteria can also cause serious illness and hospitalization in infants and young children. Prevention remains one of our most effective tools. The Lung Health Foundation supports efforts to improve access to infant pneumococcal vaccination and help families make informed decisions that can protect children’s health from the earliest years of life.”
— Jenna Benoit, PhD, Immunologist and Lead, Health Promotion & Programs (Immunization), Lung Health Foundation
“Every parent of a child with asthma knows how quickly a respiratory infection can become a frightening night in the emergency department. With more than 850,000 children in Canada living with asthma, protecting young lungs from the start is a priority. Pneumococcal disease is preventable, and families deserve the broadest protection available. Asthma Canada supports the call to offer PCV20 to every infant in the Atlantic region.”
— Jeffrey Beach, President & CEO, Asthma Canada
About the Pneumonia Awareness Consortium
The Pneumonia Awareness Consortium is a collaboration of health advocates, including non-governmental organizations, dedicated to spreading evidence-based knowledge and preventing respiratory diseases through education, outreach and community support. The Society for Intelligence Management (SIM) provides secretariat support. Learn more at pneumoawareness.ca.
On National Child Day, the Pneumonia Awareness Consortium released a position statement today asking the four Atlantic provinces to offer the 20-valent pneumococcal conjugate vaccine (PCV20) to every infant in their routine immunization programs.
Pneumococcal bacteria cause invasive pneumococcal disease, including meningitis, bloodstream infections and pneumonia. Young children are among those at greatest risk. Infants in Atlantic Canada currently receive the 15-valent vaccine (PCV15). British Columbia moved its routine infant program to PCV20 in July 2025, and Québec followed in 2026.
The five serotypes PCV20 adds to PCV15 accounted for roughly one in four invasive pneumococcal disease isolates from Canadian children under five in 2023, including the most common serotype in infants under two, according to national surveillance data.
Canada’s National Advisory Committee on Immunization considers both PCV15 and PCV20 appropriate for healthy children, and expects PCV20, with its five additional serotypes, to have a larger impact on invasive pneumococcal disease.
The statement asks provincial governments to:
• offer PCV20 to every infant in the routine program;
• act together as a region, sharing implementation tools, public messaging and clinician training;
• ensure children at higher risk receive PCV20 on the four-dose schedule recommended nationally;
• measure and report results each year, starting with vaccine coverage and serotype-specific disease in young children.
The consortium also commends the public health teams, immunizers and families across the region whose work has built strong infant vaccination programs in all four provinces.
A message for parents: Keep your child’s vaccines on schedule. The vaccine Atlantic infants receive today protects well against the 15 serotypes it covers. Parents with questions should speak with their health-care provider or local public health office.
The full statement, Every Canadian Atlantic Child, Equally Protected, is available in English and French at https://pneumoawareness.ca/every-atlantic-canadian-child-equally-protected/.
Quotes
“Pneumococcal meningitis and bloodstream infections can progress quickly in young children, and some children are left with lasting hearing loss or neurological disability. Where a child is born shouldn’t decide how broadly they’re protected. Atlantic provinces have strong infant immunization programs, and offering PCV20 to every baby is a natural next step that builds on that work.”
— Craig Thompson, Chair, Society for Intelligence Management (SIM) Canada and the Pneumonia Awareness Consortium
“When we talk about protecting children’s lung health, flu and RSV often dominate the conversation. Yet pneumococcal bacteria can also cause serious illness and hospitalization in infants and young children. Prevention remains one of our most effective tools. The Lung Health Foundation supports efforts to improve access to infant pneumococcal vaccination and help families make informed decisions that can protect children’s health from the earliest years of life.”
— Jenna Benoit, PhD, Immunologist and Lead, Health Promotion & Programs (Immunization), Lung Health Foundation
“Every parent of a child with asthma knows how quickly a respiratory infection can become a frightening night in the emergency department. With more than 850,000 children in Canada living with asthma, protecting young lungs from the start is a priority. Pneumococcal disease is preventable, and families deserve the broadest protection available. Asthma Canada supports the call to offer PCV20 to every infant in the Atlantic region.”
— Jeffrey Beach, President & CEO, Asthma Canada
About the Pneumonia Awareness Consortium
The Pneumonia Awareness Consortium is a collaboration of health advocates, including non-governmental organizations, dedicated to spreading evidence-based knowledge and preventing respiratory diseases through education, outreach and community support. The Society for Intelligence Management (SIM) provides secretariat support. Learn more at pneumoawareness.ca.
Lucie Marisa Bucci
Society for Intelligence Management (SIM)
+1 514-912-4516
advocacy@intelsociety.org
Visit us on social media:
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

